The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial
Open accessAbstract
Introduction: Benzodiazepines and α 2 adrenoceptor agonists exert opposing effects on innate immunity and mortality in animal models of infection. We hypothesized that sedation with dexmedetomidine (an α 2 adrenoceptor agonist), as compared with lorazepam (a benzodiazepine), would provide greater improvements in clinical outcomes among septic patients than among non-septic patients. Methods: In this a priori -determined subgroup analysis of septic vs non-septic patients from the MENDS double-blind randomized controlled trial, adult medical/surgical mechanically ventilated patients were randomized to receive dexmedetomidine-based or lorazepam-based sedation for up to 5 days. Delirium and other clinical outcomes were analyzed comparing sedation groups, adjusting for clinically relevant covariates as well as assessing interactions between sedation group and sepsis. Results: Of the 103 patients randomized, 63 (31 dexmedetomidine; 32 lorazepam) were admitted with sepsis and 40 (21 dexmedetomidine; 19 lorazepam) without sepsis. Baseline characteristics were similar between treatment groups for both septic and non-septic patients. Compared with septic patients who received lorazepam, the dexmedetomidine septic patients had 3.2 more delirium/coma-free days (DCFD) on average (95% CI for difference, 1.1 to 4.9), 1.5 (-0.1, 2.8) more delirium-free days (DFD) and 6 (0.3, 11.1) more ventilator-free days (VFD). The beneficial effects of dexmedetomidine were more pronounced in septic patients than in non-septic patients for both DCFDs and VFDs (P-value for interaction = 0.09 and 0.02 respectively). Additionally, sedation with dexmedetomidine, compared with lorazepam, reduced the daily risk of delirium [OR, CI 0.3 (0.1, 0.7)] in both septic and non-septic patients (P-value for interaction = 0.94). Risk of dying at 28 days was reduced by 70% [hazard ratio 0.3 (0.1, 0.9)] in dexmedetomidine patients with sepsis as compared to the lorazepam patients; this reduction in death was not seen in non-septic patients (P-value for interaction = 0.11). Conclusions: In this subgroup analysis, septic patients receiving dexmedetomidine had more days free of brain dysfunction and mechanical ventilation and were less likely to die than those that received a lorazepam-based sedation regimen. These results were more pronounced in septic patients than in non-septic patients. Prospective clinical studies and further preclinical mechanistic studies are needed to confirm these results. Trial Registration: NCT00095251.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885 · cited 1×
“The proportional hazards assumption for time to death within 28 days was validated graphically and via examining model residuals [50].”
Sessler, C. N., Gosnell, M. S., Grap, M. J., Brophy, G. M., O'Neal, P. V., Keane, K. A., Tesoro, E. P., & Elswick, R. K. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2107138 · Cited by 3,695
Ely, E. W., Inouye, S. K., Bernard, G. R., Gordon, S., Francis, J., May, L., Truman, B., Speroff, T., Gautam, S., Margolin, R., et al. (2001) · JAMA · doi:10.1001/jama.286.21.2703 · Cited by 3,210
Self-citationDelirium as a Predictor of Mortality in Mechanically Ventilated Patients in the Intensive Care Unit
Ely, E. W. (2004) · JAMA · doi:10.1001/jama.291.14.1753 · Cited by 3,073
Self-citationNelson, L. E., Lu, J., Guo, T., Saper, C. B., Franks, N. P., & Maze, M. (2003) · Anesthesiology · doi:10.1097/00000542-200302000-00024 · Cited by 854
Self-citationDelirium in an intensive care unit: a study of risk factors
Dubois, M.-J., Bergeron, N., Dumont, M., Dial, S., & Skrobik, Y. (2001) · Intensive Care Medicine · doi:10.1007/s001340101017 · Cited by 609 · cited 1×
“Benzodiazepines, in particular, enhance the risk of developing acute brain dysfunction [6,16-18].”
Sharshar, T., Gray, F., de la Grandmaison, G. L., Hopklnson, N. S., Ross, E., Dorandeu, A., Orlikowski, D., Raphael, J.-C., Gajdos, P., & Annane, D. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14899-4 · Cited by 341
Cytokines and acute phase response in delirium
de Rooij, S. E., van Munster, B. C., Korevaar, J. C., & Levi, M. (2007) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2006.11.013 · Cited by 261
Cited by
Long-term complications of critical care
Desai, S. V., Law, T. J., & Needham, D. M. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181fd66e5 · Cited by 870
Sepsis-associated encephalopathy
Gofton, T. E., & Young, G. B. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.183 · Cited by 821
Interventions for preventing delirium in hospitalised non-ICU patients
Siddiqi, N., Harrison, J. K., Clegg, A., Teale, E. A., Young, J., Taylor, J., & Simpkins, S. A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005563.pub3 · Cited by 619
Unresponsiveness ≠ unconsciousness
Sanders, R. D., Tononi, G., Laureys, S., Sleigh, J. W., & Warner, D. S. (2012) · Anesthesiology · doi:10.1097/aln.0b013e318249d0a7 · Cited by 474
Self-citationDexmedetomidine: present and future directions
Lee, S. (2019) · Korean Journal of Anesthesiology · doi:10.4097/kja.19259 · Cited by 367
Metadata
- Authors
- Pandharipande, P. P., Sanders, R. D., Girard, T. D., McGrane, S., Thompson, J. L., Shintani, A. K., Herr, D. L., Maze, M., Ely, E. W., & the MENDS investigators
- Venue
- Critical Care
- Published
- 2010-03-16
- Volume
- 14
- Issue
- 2
- Pages
- R38-R38
- ISSN
- 1364-8535 (ISSN-L)
- OpenAlex
- W1984552110
- Cited by
- 410
- References
- 8
- FWCI
- 24.19
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial. https://app.cochat.ai/papers/10.1186/cc8916
- The paper
- Pandharipande, P. P., Sanders, R. D., Girard, T. D., McGrane, S., Thompson, J. L., Shintani, A. K., Herr, D. L., Maze, M., Ely, E. W., & the MENDS investigators. (2010). Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial. Critical Care. https://doi.org/10.1186/cc8916
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.